Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics ...
Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the ...
In a real-world study, UPCR decreased when darbepoetin alfa dose exceeded 60 μg in patients with diabetic kidney disease. Darbepoetin alfa treatment is associated with proteinuria lowering in a ...
In 2025, the FDA approved 73 first-time generic drugs. Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...
Complete blood count, especially neutrophil and hemoglobin values, may provide a window into the neurologic risk of patients with CKD, possibly identifying individuals who warrant closer brain health ...
News Medical on MSN
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class ...
Fresenius Medical Care, a major provider of renal disease products, will start the new year with a new global chief medical ...
Kidney disease doesn’t arrive with sirens. It doesn’t announce itself loudly. Most of the time, it slips in quietly, doing ...
Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback